AcelRx Pharmaceuticals In... (ACRX)
NASDAQ: ACRX
· Real-Time Price · USD
0.86
0.06 (7.50%)
At close: Jan 09, 2024, 10:00 PM
AcelRx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -8.56M | -5.07M | -6.99M | -9.23M | -10.24M | -18.4M | -21.36M | -26.76M | 48.28M | 47.76M | 47.32M | 45.7M | -34.82M | -35.1M | -36.1M | -36.66M | -33.41M |
Depreciation & Amortization | -553K | -553K | -553K | -121K | 49K | 311K | 653K | 1.08M | 1.49M | 1.65M | 1.77M | 1.82M | 1.94M | 1.97M | 1.89M | 1.9M | 1.82M |
Stock-Based Compensation | 167K | 1K | 116K | 923K | 1.16M | 1.73M | 2.07M | 2.39M | 2.67M | 2.89M | 3.36M | 3.88M | 4.3M | 4.61M | 4.57M | 4.45M | 4.37M |
Other Working Capital | 761K | 761K | 535K | 524K | -1.05M | -463K | -441K | 77K | 114K | -1.69M | -2.91M | -461K | 331K | -88K | 1.62M | -882K | -4.68M |
Other Non-Cash Items | -788K | -1.16M | -99K | -2.55M | -2.5M | -1.22M | -341K | 1.49M | -77.41M | -79.23M | -80.87M | -81.35M | -1.98M | -2.5M | -2.45M | -2.51M | -2.63M |
Deferred Income Tax | -1.23M | -1.23M | -1.23M | n/a | 1.23M | 1.23M | 1.23M | 1.23M | n/a | n/a | 810K | 810K | 810K | 810K | n/a | n/a | n/a |
Change in Working Capital | 2.47M | 2.47M | 2.33M | 732K | -2.33M | -1.54M | -1.2M | -664K | 321K | -1.39M | -3.32M | -496K | 509K | 203K | 3.77M | 308K | -3.99M |
Operating Cash Flow | -8.49M | -5.55M | -6.03M | -9.85M | -12.24M | -17.49M | -18.96M | -21.23M | -24.65M | -28.33M | -30.92M | -29.63M | -29.23M | -30M | -28.32M | -32.51M | -33.85M |
Capital Expenditures | 100K | 100K | 100K | n/a | n/a | -100K | -148K | -306K | -375K | -364K | -344K | -370K | -1.89M | -1.83M | -3.43M | -3.3M | -1.81M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | -1.69M | -1.69M | -1.69M | -2.84M | -1.16M | -1.16M | -1.16M | n/a | n/a | n/a | n/a |
Purchase of Investments | -4.98M | -4.98M | -8.63M | -3.65M | -3.65M | -3.65M | -492K | -492K | -1.69M | -7.86M | -23.96M | -39.63M | -52.19M | -70.46M | -59.66M | -54.01M | -56.3M |
Sales Maturities Of Investments | 8.86M | 8.86M | 8.86M | 600K | n/a | 500K | 3.7M | 8.3M | 19.27M | 46.36M | 56.16M | 60.76M | 67.54M | 46.98M | 47.18M | 46.83M | 52.16M |
Other Investing Acitivies | -2.72M | -2.72M | -2.72M | n/a | 2.72M | 2.72M | 4.41M | 4.41M | 1.16M | 1.16M | -1.35M | -1.35M | -821K | -821K | n/a | n/a | n/a |
Investing Cash Flow | 1.26M | 1.26M | -2.39M | -3.05M | -928K | -528K | 5.78M | 10.22M | 16.67M | 36.45M | 29.35M | 18.26M | 11.48M | -26.12M | -15.91M | -10.47M | -5.94M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | 25K | 25K | 25K | 3K | n/a | -22K | -22K | -22K | -22K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -22K | -22K | -22K | n/a | n/a | -22K | -22K | -22K | -22K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 18.28M | 13.93M | 13.93M | 8.97M | 5.61M | 3.56M | 8.85M | -1.72M | -474K | -507K | 6.03M | 5.21M | 5.21M | 41.51M | 37.53M | 47.52M | 50.26M |
Financial Cash Flow | 12.89M | 8.54M | 8.47M | 8.9M | 5.54M | 3.47M | 8.83M | -1.75M | -496K | -507K | 6.03M | 5.21M | 5.21M | 41.51M | 37.53M | 47.52M | 50.26M |
Net Cash Flow | -8.9M | -10.31M | -6.83M | 3.67M | 36K | -6.89M | -4.34M | -12.76M | -8.47M | 7.61M | 4.46M | -6.16M | -12.54M | -14.61M | -6.7M | 4.54M | 10.48M |
Free Cash Flow | -8.39M | -5.45M | -5.92M | -9.85M | -12.24M | -17.59M | -19.1M | -21.54M | -25.02M | -28.7M | -31.27M | -30M | -31.12M | -31.83M | -31.75M | -35.81M | -35.66M |